Schaffrin-Nabe Doerthe, Josten-Nabe Anke, Heinze Adrian, Tannapfel Andrea, Schaffrin Merle, Voigtmann Rudolf
Praxis für Hämatologie und Onkologie, Bochum, 44799, Germany.
Noack Statistik GmbH, Bonn, 53119, Germany.
Cancer Manag Res. 2025 Jun 30;17:1245-1257. doi: 10.2147/CMAR.S526775. eCollection 2025.
Scalp cooling has emerged as a promising intervention for mitigating chemotherapy-induced alopecia, particularly in patients undergoing anthracycline- and taxane-based regimens typically associated with complete hair loss. Despite a visible hair retention rate of 53%, efficacy varies significantly among individuals, influenced by modifiable factors including general health, hair follicle characteristics, and treatment protocols.
This study evaluated 81 breast cancer patients treated with Epirubicin/Cyclophosphamide followed by weekly Paclitaxel application. Hair preservation was assessed using a cross-section trichometer (Cohen Hair Mass Index [HMI]), light microscopy, and scanning electron microscopy. Key parameters evaluated included pre- and posttherapeutic trichological characteristics such as bulb diameter, shaft diameter, anagen rate, as well as grade of hair shaft damage.
A total of 53% of patients retained visible hair post-treatment (HMI ≥ 50). Trichological factors-particularly bulb diameter, shaft diameter, and anagen rate-strongly predicted hair preservation outcomes. Additionally, hair shaft integrity, specifically surface damage grading, emerged as a critical determinant of clinically meaningful hair retention.
Scalp cooling's protective effect extends beyond aesthetics, significantly supporting psychological well-being during cancer treatment. Emerging strategies, including cell cycle modulation, antioxidant-based treatments, offer promising avenues to enhance follicular and shaft resilience. While these require further clinical validation, the findings highlight the potential to improve scalp cooling outcomes and raise the standard of supportive oncologic care.
头皮冷却已成为一种有前景的干预措施,用于减轻化疗引起的脱发,特别是在接受通常会导致完全脱发的基于蒽环类药物和紫杉烷类药物方案治疗的患者中。尽管可见毛发保留率为53%,但个体间的疗效差异显著,受一般健康状况、毛囊特征和治疗方案等可改变因素的影响。
本研究评估了81例接受表柔比星/环磷酰胺治疗后每周应用紫杉醇的乳腺癌患者。使用横断面毛发测量仪(科恩毛发质量指数[HMI])、光学显微镜和扫描电子显微镜评估毛发保留情况。评估的关键参数包括治疗前后的毛发学特征,如毛囊球直径、毛干直径、生长期比率以及毛干损伤程度。
共有53%的患者治疗后保留了可见毛发(HMI≥50)。毛发学因素,特别是毛囊球直径、毛干直径和生长期比率,强烈预测了毛发保留结果。此外,毛干完整性,特别是表面损伤分级,成为临床上有意义的毛发保留的关键决定因素。
头皮冷却的保护作用不仅限于美观,在癌症治疗期间对心理健康有显著支持作用。包括细胞周期调节、基于抗氧化剂的治疗等新兴策略提供了增强毛囊和毛干弹性的有前景途径。虽然这些需要进一步的临床验证,但研究结果突出了改善头皮冷却效果和提高支持性肿瘤护理标准的潜力。